-
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
09 Dec 2025 13:07 GMT
… Orphan Drug Designation from the FDA for the treatment of … Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical … 3 trial evaluating Annamycin in combination with cytarabine, together … to conduct its clinical trials as described in …
-
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile
09 Dec 2025 12:00 GMT
… ”), a clinical-stage biotechnology company developing next-generation … standard of care treatment
This safety profile … including Ara-C (cytarabine), and most had … Drug Administration (FDA) has granted Orphan Drug Designation (ODD) and Regenerative Medicine …
-
Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma
06 Dec 2025 14:58 GMT
… controlled clinical trials are warranted … Zhongguancun Precision Medicine Science and Technology … Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab … treatment of central nervous system lymphoma: a retrospective study. Invest New Drugs …
-
<![CDATA[What Adverse Effects May Occur During Acute Myeloid Leukemia Treatment?]]>
02 Dec 2025 09:37 GMT
… with AML might experience during treatment, Peters, an assistant … the Department of Medicine at the Medical College of Georgia … is an anthracycline along with cytarabine. These are the [adverse … Going down the lower intensity treatment pathway, the standard of …
-
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
02 Dec 2025 16:08 GMT
… . Food and Drug Administration (FDA) for the treatment of adult patients … decitabine, or low-dose cytarabine to treat adults with … type of immunization or vaccine, ask your healthcare provider … VENCLEXTA. Call your doctor for medical advice about side effects …
-
A new generation of AML treatments brings hope for better survival
02 Dec 2025 02:20 GMT
… Medicine, the updated 2025 American Society of Hematology (ASH) AML treatment … have led to FDA approval of three drugs to treat … hard questions that patients and doctors ask, and I… decitabine) or low-dose cytarabine. These treatments can be combined with …
-
<![CDATA[Imbruvica Plus Drug Combo Shows Strong Responses in Newly Diagnosed PCNSL]]>
25 Nov 2025 07:18 GMT
… whose cancer completely disappears with treatment.
Overall response rate (ORR): percentage … cancer shrinks or disappears after treatment.
Progression-free survival (PFS): time … plus cytarabine in this patient population.
Furthermore, a phase 2 trial showed …
-
Moleculin Biotech inks research & material transfer agreement with University of North Carolina to evaluate Annamycin for treatment of pancreatic cancer
15 Nov 2025 06:29 GMT
… Biotech Inc, a late-stage pharmaceutical company with a broad portfolio of drug … announced investigator-funded clinical trial in pancreatic cancer … Orphan Drug Designation from the FDA for the treatment of … in combination with cytarabine (also known as …
-
Decitabine Enhances Treatment for High-Risk AML Patients
15 Nov 2025 10:46 GMT
… CAG, which typically comprises cytarabine and other agents, is … in the clinical trials associated with this research … to utilize existing drugs in novel ways … Decitabine, Modified CAG, Personalized Medicine, Treatment Efficacy.
Tags: combination therapy …
-
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
13 Nov 2025 13:36 GMT
… Orphan Drug Designation from the FDA for the treatment of … Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical … 3 trial evaluating Annamycin in combination with cytarabine, together … to conduct its clinical trials as described in …
About
© 1995-2025